Effect of chronic acamprosate treatment on voluntary alcohol intake and β-endorphin plasma levels in rats selectively bred for high alcohol preference
Section snippets
Acknowledgements
This study was supported by the Medical University of Lodz, Poland (grants 502-13-490 and 503-3011-1).
References (48)
- et al.
Classification of alcoholics on the basis of plasma β-endorphin concentration
Alcohol
(1995) - et al.
Use of silicic acid extraction and reversed-phase columns for rapid purification prior to radioimmunoassay
J. Chromatogr.
(1982) - et al.
Mu-opioid receptor binding measured by [11C] carfentanil positron emission tomography is related to craving and mood in alcohol dependence
Biol. Psychiatry
(2004) - et al.
A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?
Pharmacol. Biochem. Behav.
(1984) - et al.
Acamprosate for the treatment of alcohol dependence
Clin. Ther.
(2005) - et al.
The ethanol self-administration context as a reinstatement cue: acute effects of naltrexone
Neuroscience
(2006) - et al.
Effect of selective blockade of mu (1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats
Neuropsychopharmacology
(2002) - et al.
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats
Neuropsychopharmacology
(1998) - et al.
Effects of treatment with acamprosate on β-endorphin plasma concentration in humans with high alcohol preference
Neurosci. Lett.
(2006) - et al.
An in vivo profile of β-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol
Neuroscience
(2004)
Endorphins and experimental addiction
Alcohol
Sex differences in schedule-induced alcohol consumption
Alcohol
Changes in the beta endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference
Neurosci. Lett.
Rewarding properties of beta-endorphin as measured by conditioned place preference
Psychopharmacology
The endorphins: a growing family of pharmacologically pertinent peptides
Ann. Rev. Pharmacol. Toxicol.
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
Addiction
The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system
Addict. Biol.
Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism
Alcohol. Clin. Exp. Res.
Neuroprotective and abstinence-promoting effects of acamprosate. Elucidating the mechanism of action
CNS Drugs
Alcohol dopamine
Alcohol Health Res. World
Animal model of ethanol abuse: rats selectively bred for high and low voluntary alcohol intake
Acta Pol. Pharm. Drug Res.
Preliminary phenotypic characterization of the Warsaw High Preferring (WHP) and Warsaw Low Preferring (WLP) lines of rats selectively bred for high and low ethanol consumption
Pol. J. Pharmacol.
Immunocytochemical localization of β-endorphin-containing neurons in the rat brain
Neuroendocrinology
Endogenous opioids and addiction to alcohol and other drugs of abuse
Curr. Top. Med. Chem.
Cited by (14)
Unconventional anxiety pharmacology in zebrafish: Drugs beyond traditional anxiogenic and anxiolytic spectra
2021, Pharmacology Biochemistry and BehaviorCitation Excerpt :Administered alone, naloxone evokes no behavioral activity in mammals (Belzung and Agmo, 1997; Belzung and Ågmo, 1997), but induces anxiogenic-like bottom swimming with frequent short hyperactivity bouts in zebrafish (Stewart et al., 2011). These findings suggest that opioid antagonists can trigger anxiety in zebrafish by non-selectively inhibiting endogenous opioids (that, in turn, may have higher baseline levels in fish vs. mammals, see Nakao et al., 1978; Pottinger et al., 1995; Zalewska-Kaszubska et al., 2008 for details). For instance, baseline plasma β-endorphin levels are 5-fold higher in some teleost fish (e.g., rainbow trout) (Pottinger et al., 1995) than in rats (Zalewska-Kaszubska et al., 2008), and are >100-fold higher than in humans (Nakao et al., 1978).
Rat animal models for screening medications to treat alcohol use disorders
2017, NeuropharmacologyVoluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with lamotrigine
2015, Physiology and BehaviorCitation Excerpt :Perhaps the lack of effect of lamotrigine on the opioid system, as seen by Hajhashemi and Abed-Natanzi [39] was the reason for its ineffectiveness in suppression of naloxone-precipitated opiate withdrawal syndrome. In contrast to lamotrigine, topiramate, which was effective in the above test, affects the opioid system similarly to acamprosate and naltrexone, the most effective drugs in the treatment of alcohol addiction [40,41]. In the present study we have observed that the beta-endorphin level, in rats without access to ethanol, didn't change and was similar both in groups treated and untreated with lamotrigine.
Acamprosate {monocalcium bis(3-acetamidopropane-1-sulfonate)} reduces ethanol-drinking behavior in rats and glutamate-induced toxicity in ethanol-exposed primary rat cortical neuronal cultures
2013, European Journal of PharmacologyCitation Excerpt :The daily dose of 200 mg/kg acamprosate used in the present study is greater than the clinical dose of about 40 mg/kg daily used for the treatment of alcohol dependence. However, a dose of 200 mg/kg is commonly used to study the effect of this compound in animal models (Gupta et al., 2008; Olive et al., 2002; Spanagel et al., 1996; Zalewska-Kaszubska et al., 2008). Acamprosate reduced ethanol consumption during the treatment period, and the reduction was significant from day 6 to day 8 and from day 11 to day 15 (Fig. 1B and Table 1).
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: A preliminary study
2011, Physiology and BehaviorCitation Excerpt :Our previous studies demonstrated that repeated treatment with acamprosate and naltrexone, the most effective drugs in the treatment of alcohol addiction, resulted in an increase of beta-endorphin concentrations in the rats' plasma. The beta-endorphin increase was accompanied by a decrease in voluntary alcohol intake by alcohol preferring rats [15,16]. We have also found that topiramate increases the levels of beta-endorphin [17].
Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1
2011, Neuroscience Letters